50 results about "Ginsenoside rg2" patented technology

The invention discloses a ginsenoside-containing medicine composition. The ginsenoside-containing medicine composition comprises the following active ingredients by weight percent: 20-70 percent of ginsenoside Rg, 10-40 percent of ginsenoside Rh2 and 20-50 percent of notoginsenoside ft1. The invention also provides application of the composition to drugs for preventing and treating cancers, auxiliary anti-cancer drugs and medicines or health products used for strengthening the organic immunity. The ginsenoside-containing medicine composition can effectively inhibit tumor cells and stimulate lymphocyte proliferation, has excellent pharmacological effects, and has better security on the basis of saving resources and taking better drug effects.

The present invention relates to kind one ginsenoside Rg2 preparing process suitable for industrial production, and gradient salt separation process with simple operation is used in substituting traditional silicon gel chromatography process. The present invention also relates to medicine composition with ginsenoside Rg2 as active component and its application in medicine for preventing and treating dementia, depression, peripheral circulation disturbance and related diseases.

The present invention discloses an inclusion complex containing the panaxsaponin Rg₂ and the preparation method. The inclusion complex of the invention consists of the panaxsaponin Rg₂ and the hydroxypropyl-Beta-cyclodextrin. The preparation method of the present invention is as following. The hydroxypropyl-Beta-cyclodextrin water solution is prepared; the hydroxypropyl-Beta-cyclodextrin solution is kept in the water bath; the extraction powder of the panaxsaponin Rg₂ or the extraction of the liquid-typed Rg₂ dissoluted by the solvent is added before mixing and complex; therefore the liquid inclusion complex is obtained and the inclusion complex after drying. The inclusion complex of the present invention has functions of increasing the heart perfusion and the blood flow, expanding the diameter of the vein and the artery, improving the microcirculation disturbance, improving the myocardial ischemia and anti-thrombosis effect. The present invention can significantly reduce the acute toxicity of the panaxsaponin Rg₂.

The invention relates to a panaxatriol saponin composition, wherein active components with immune-enhancing function in the composition mainly comprise ginsenoside-Re, ginsenoside-Rg1, ginsenoside-Rg2 and ginsenoside-Rh1, and the components in percentage by weight are: 25 to 50 percent of the ginsenoside-Re, 15 to 50 percent of the ginsenoside-Rg1, 0 to 30 percent of the ginsenoside-Rg2, and 0 to 30 percent of the ginsenoside-Rh1. The panaxatriol saponin composition of the proportions has the immune-enhancing activity far larger than that of a ginseng monomer saponin, improves the curative effect of the immune-enhancing function, and reduces the toxic side effects. In addition, the preparation method is simple, and the production cost is low.

The invention relates to the technical field of medical treatment, in particular to application of ginsenoside CK in the preparation of external drugs and health cosmetics to treat atopic dermatitis.OVA-sensitized (ovalbumin-sensitized) atopic dermatitis mouse models are established; filaggrin gene-deficient atopic dermatitis mice are selected; the two types of mice are fed with ginsenoside CK with different concentrations. The results show that ginsenoside CK can evidently reduce the scratching frequency of the OVA- sensitized AD (atopic dermatitis) model mice and reduce epidermal and dermalthickness of the mice; the therapeutic effect of a medium concentration group and that of the high concentration group are evidently higher than that of the low concentration group and that of a dexamethasone cream group; ginsenoside CK can reduce dermatitis score and scratching frequency of Ft mice and the expression of IL-4 at skin lesions of the Ft mice, the therapeutic effect of the medium concentration group is higher than that of the low concentration group and that of the high concentration group, and dexamethasone cream cannot improve atopic dermatitis type skin lesions with skin barrier dysfunction caused by filaggrin gene deficiency. The external drugs and health cosmetics made with ginsenoside CK herein have the advantages of good therapeutic effect and good safety.

The invention discloses a rhizopus stolonifer capable of biologically converting ginsenosides. A fermentation product is analyzed by an HPLC (High Performance Liquid Chromatography) system to prepare a component with a reduced color spectrum peak value in an original panaxatriol saponins and a component with an increased peak value in the panaxatriol saponins fermentation product thereof. By isolation and identification, a converted substance in the panaxatriol saponins is confirmed to be ginsenosides Re, a compound (1) in the panaxatriol saponins fermentation product is confirmed to be ginsenosides Rh1, a compound (2) is confirmed to be ginsenosides Rg3, and a compound (3) is confirmed to be ginsenosides Rg2. By speculation, the ginsenosides Re in the panaxatriol saponins is converted into the ginsenosides Rh1 by the black rhizopus or the ginsenosides Re is firstly converted into the ginsenosides Rg2 and then converted into ginsenosides Rh1, and the detailed conversion path is to be further researched.

Beneficial effects are obtained by topically applying ginsenoside F2 to the skin to improve skin conditions, improve water content on the skin surface and related benefits improving skin problems associated with acne or atopy, providing a skin whitening effect, helping control of sebaceous secretion, tightening skin pores, or improving skin complexion through enhanced blood circulation, but also to improve scalp and hair conditions, such as providing an anti-dandruff effect, promoting hair growth, or preventing generation of grey hair.

The invention discloses a preparation method of a novel ginsenoside--dihydro ginsenoside Rg2, which has more than 80 percent of yield and is suitable for industrial production. The dihydro ginsenoside Rg2 has the functions of preventing or treating diseases related to microcirculatory disturbance.

The present invention relates to a semisynthesis method of 20(s)-ginsenoside Rgz. It includes the following steps: dissolving the raw material ginsenoside Re in 20-30% ethyl alcohol aqueous solution with 0.01-0.05 MHCl, heating for 2-3 hr, in water bach with 70-80 deg.c, cooling, making said solution pass through anion exchange resin, removing acid and collecting effluent, recovering solvent to obtain ginsenoside Rgz crude product, then using methyl alcohol-ethyl acetate to make said crude product be repeatedly recrystallized to make purification or making said crude product undergo the process of silica-gel column chromatographic treatment and using chloroform-methyl alcohol-water as eluent, collecting ginsenoside Rg2 portion.

The invention belongs to the field of medicine or natural medicine chemistry, and particularly relates to application of a natural product-ginsenoside Rb3 in preparing a medicine for treating depressive disorder. In the application, ginsenoside Rb3 is directly extracted and obtained from panax notoginseng, ginseng or American ginseng; the dosage is 3.0-20.0mg per kilo of weight each day. Through organically regulating in vivo neurotransmitter and neural network balance and actions of multiple ways and multiple targets such as promoting nerve growth and the like, ginsenoside Rb3 is applied in preparing medicine for treating depressive disorder, so that obvious anti-depression effect is obtained. In addition, ginsenoside Rb3 can be extracted and obtained through traditional Chinese medicine or natural plants, and can be supplied for patients with depressive disorder to be continuously taken for a long period. The ginsenoside Rb3 has clear effective substance, obvious therapeutic effect, small toxic or side effect and definite action mechanism, and is in favor of radically treating depressive disorder and avoiding recurrence of depressive disorder.

The invention relates to a group of high-activity glycosyl transferases responsible for sugar chain extension and an application of the glycosyl transferases. Specifically, the invention provides glycosyl transferase and a derivative polypeptide thereof, which can efficiently catalyze the reaction of extending sugar chains on the first glycosyl at the C-20 site and the first glycosyl at the C-6 site of a tetracyclic triterpenoid substrate. The ginsenoside products such asginsenoside Rb1, the ginsenoside Rb3, the ginsenoside DMGG, the ginsenoside DMGX, the gynostemma pentaphyllum saponin LXXV, the gynostemma pentaphyllum saponin XVII, the gynostemma pentaphyllum saponin XIII, gynostemma pentaphyllum saponin IX, notoginsenoside U and the notoginsenoside R1, notoginsenoside R2, notoginsenoside R3, 3-O-beta-(D-xylopyranosyl)-beta-(D-glucopyranosyl)-CK, 20-O-glucosyl ginsenoside Rf, Rd-C20-O-Rha, ginsenoside Rg2, and ginsenoside Re and the like can be obtained. The glycosyl transferase disclosed by the invention can also be applied to construction of artificially synthesized ginsenoside and a plurality of new ginsenosides and derivatives thereof.

The present invention relates to a pharmaceutical composition for preventing or treating Gleevec-resistant leukemia, containing, as an active ingredient, ginsenoside F1 or Rg3 which exhibits a preventive or therapeutic effect on Gleevec-resistant leukemia through enhancing cell killing activity of NK cells; a method for treating Gleevec-resistant leukemia comprising a step of administering the pharmaceutical composition; and a food composition for preventing or ameliorating Gleevec-resistant leukemia. Since the pharmaceutical composition of the present invention can effectively treat leukemia that exhibits resistance to conventional Gleevec, the pharmaceutical composition can be widely used for effective leukemia treatment.

The invention relates to a method for preparing rare ginsenoside Rg2. According to the method, Cellulosimicrobium sp.21 serves as fermented culture biotransformation total saponins of panax ginseng. By means of the method, the high-quality rare ginsenoside Rg2 can be efficiently prepared.

The invention discloses a composition, a pharmaceutical preparation and an application. The composition comprises 1-5 parts by mass of ginsenoside Rg2,10-20 parts by mass of at least one of bamboo-leaves flavones, orientoside, Isoorientin, agnoside and isovitexin, and 15-25 parts by mass of taurine or pharmaceutically acceptable salt thereof. The composition can effectively prevent and/or treat cardiovascular and cerebrovascular diseases.

The invention discloses a use of ginsenoside Rg1 in preparation of drugs for treating fatty liver. The invention discovers the new medicinal value of ginsenoside Rg1 and develops its application field. The ginsenoside Rg1 can effectively improve high fat diet-induced liver damage and steatosis. The ginsenoside Rg1 is further used in treatment and remission of fatty liver. The invention provides adrug for treating fatty liver. The drug is prepared only from the ginsenoside Rg1 monomer and is used for treating fatty liver. The drug has good effects of treating and improving non-alcoholic fattyliver.

The invention discloses a method for efficiently and rapidly preparing and separating three kinds of ginsenoside isomers Rg6, Z type and E type F4. The preparation method of a saponin mixture is as follows: ginsenoside Rg2 is used as a raw material, an acid-containing alcohol-water solution is used as a reaction system, a thermal dehydration reaction is carried out, and lead dioxide is used as a catalyst. A separation method of the saponin mixture is as follows: high-speed countercurrent chromatography is used for separation, and ethyl acetate-ethanol-water-acetic acid (volume ratio is 4:1:5:0.08) is used as a solvent system. The method for preparing a mixture of ginsenoside isomers Rg6, Z type and E type F4 has high yield, 90% or above of ginsenoside Rg2 is converted into Rg6, (Z)-F4 and (E)-F4, and utilization rate of raw materials is high; The method for separating the mixture of ginsenoside isomers Rg6, Z type and E type F4 by high speed countercurrent has high separation efficiency and good separation degree, three kinds of isomers can be effectively separated, and once separation is carried out in order to obtain three kinds of isomers, wherein each mass of the isomers is 100mg or above.

The invention provides a composition for improving kidney dysfunction and belongs to the technical field of ginseng deep-processing. The composition comprises, by weight, 2-6 parts of ginsenoside Rg2,1-5 parts of ginsenoside Rg5 and 1-3 parts of ginsenoside Rk1. The composition participates in slowing down the progress of chronic kidney interstitial fibrosis by inhibiting HK-2 phenotypic differentiation so as to improve chronic kidney dysfunction. It is verified that the composition can remarkably improve kidney functions of patients at 2-3 stages of chronic kidney dysfunction CKD.